Valuation: Cogent Biosciences, Inc.

Market Cap 7.07B 6.14B 5.7B 5.26B 9.91B 675B 10.08B 67.5B 26.43B 335B 26.55B 25.96B 1,127B P/E 2026 *
-18.1x
P/E 2027 * -50.6x
Enterprise Value 7.01B 6.09B 5.66B 5.22B 9.83B 670B 10.01B 66.98B 26.22B 333B 26.34B 25.76B 1,118B EV / Sales 2026 *
708x
EV / Sales 2027 * 20.1x
Free-Float
99.5%
Yield 2026 *
-
Yield 2027 * -
1 day+4.52%
1 week+2.78%
Current month+6.87%
1 month+6.87%
3 months+15.56%
6 months+15.18%
Current year+16.44%
1 week 38.84
Extreme 38.84
42.11
1 month 37.04
Extreme 37.04
42.11
Current year 30.87
Extreme 30.87
42.11
1 year 10.38
Extreme 10.38
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+4.52%+2.78%+258.72%+225.41% 6.76B
-0.81%-0.33%+27.15%+81.12% 55.6B
-3.74%-6.32%+42.70%+64.45% 55.2B
-0.11%+0.86%-15.63%-13.56% 23.51B
-1.58%-5.51%-3.51%+375.36% 22.35B
+2.33%-1.07%+20.12%-12.29% 20.6B
-1.23%-3.15%+26.00%-31.88% 17.45B
+1.37%-5.14%+17.21%+545.40% 15.16B
+1.16%+0.58%+51.87%+181.96% 13.91B
-5.09%-10.87%+153.11%+272.20% 13.74B
Average -0.32%-1.38%+57.77%+168.82% 24.43B
Weighted average by Cap. -1.09%-0.44%+37.35%+128.52%

Financials

2026 *2027 *
Net sales 9.9M 8.6M 7.99M 7.37M 13.88M 945M 14.13M 94.57M 37.03M 470M 37.19M 36.37M 1.58B 349M 303M 281M 260M 489M 33.31B 498M 3.33B 1.3B 16.54B 1.31B 1.28B 55.63B
Net income -392M -340M -316M -291M -549M -37.38B -559M -3.74B -1.46B -18.57B -1.47B -1.44B -62.43B -132M -114M -106M -97.96M -185M -12.57B -188M -1.26B -492M -6.24B -495M -484M -21B
Net Debt -55.22M -47.96M -44.54M -41.08M -77.37M -5.27B -78.78M -527M -206M -2.62B -207M -203M -8.8B -63.88M -55.48M -51.52M -47.52M -89.5M -6.1B -91.12M -610M -239M -3.03B -240M -235M -10.19B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
30/07/26 $41.36 +4.52% 1,835,733
29/07/26 $39.57 -2.70% 1,220,992
28/07/26 $40.67 +0.57% 1,133,724
27/07/26 $40.44 +1.71% 1,383,712
24/07/26 $39.76 -1.19% 1,593,419
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
41.36USD
Average target price
54.25USD
Spread / Average Target
+31.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock